New York, NY, Feb. 12, 2025 (GLOBE NEWSWIRE) -- FOURTH QUARTER Total revenue, including billable expenses, was $2.9 billion Revenue before billable expenses ("net revenue") was $2.4 billion, with organic decrease of -1.8% Reported net income was $344.5 million Adjusted EBITA before restructuring charges and deal costs was $591.2 million with margin of 24.3% on revenue before billable expenses Diluted earnings per share of $0.92 as reported and $1.11 as adjusted FULL YEAR Total revenue, including billable expenses, was $10.7 billion Revenue before billable expenses ("net revenue") was $9.2 billion, with organic growth of 0.2% Reported net income was $689.5 …

TUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AML TUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patients TUS+VEN+AZA triplet shows favorable safety with no alteration of VEN and AZA dosing PK levels of TUS in the triplet remain equivalent to levels as TUS or TUS+VEN therapy SAN DIEGO and TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company, today reported promising early safety and response results from newly diagnosed acute myeloid leukemia (AML) patients dosed in Aptose's Phase 1/2 TUSCANY trial …

GREENWICH, Conn., Feb. 12, 2025 (GLOBE NEWSWIRE) -- QXO, Inc. (NYSE: QXO) announced today that it has obtained antitrust clearance in both the U.S. and Canada for its acquisition of Beacon Roofing Supply, Inc. (Nasdaq: BECN), paving the way for QXO to close the transaction quickly.

– Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –

SPARTANBURG, S.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Denny's Corporation (the "Company") (NASDAQ: DENN), owner and operator of Denny's Inc. ("Denny's") and Keke's Inc. ("Keke's") today reported results for its fourth quarter and full year ended December 25, 2024 and provided a business update on the Company's operations.

SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close.

LONDON and NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Wilmington Trust and AccessFintech have announced a new collaboration that automates and streamlines loan lifecycle management using the Synergy platform. This effort drives real-time data transparency and collaboration, significantly reducing discrepancies and resolution times among various organizations across the loan market.

Proceeds expected to fund the start of the ALG-000184 Phase 2 clinical study Funding expected to extend cash runway into the second half of 2026 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $105 million, before deducting placement agents' fees and other expenses.

MALMÖ, Sweden, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world's original and largest oat drink company, today announced financial results for the fourth quarter and twelve months ended December 31, 2024. Jean-Christophe Flatin, Oatly's CEO, commented, “Over the past two years, we have executed a significant transformation of our company.

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ:AZN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or "the Company") (NASDAQ:REGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Regeneron securities between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Micron Technology, Inc. ("Micron" or "the Company") (NASDAQ:MU) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Micron securities between September 28, 2023 and December 18, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Joint Stock Company Kaspi.kz ("Kaspi.kz" or "the Company") (NASDAQ:KSPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kaspi.kz securities between January 19, 2024 and September 19, 2024, both dates inclusive (the "Class Period").

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Transocean Ltd. ("Transocean" or "the Company") (NYSE:RIG) and certain of its officers.

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Nextracker Inc. ("Nextracker" or "the Company") (NASDAQ: NXT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Nextracker securities between February 1, 2024 and August 1, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MGP Ingredients, Inc. ("MGP Ingredients" or "the Company") (NASDAQ:MGPI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MGP Ingredients securities between May 3, 2023 and October 30, 2024, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 12, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Capri Holdings Limited ("Capri" or "the Company") (NYSE:CPRI) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Capri securities between August 10, 2023 and October 24, 2024, both dates inclusive (the "Class Period").